By InvitationNot Applicable

Precision Prevention Strategy to Increase Uptake and Engagement in Lung Cancer Screening and Smoking Cessation Treatment

United States915 participantsStarted 2023-01-01

Plain-language summary

This trial tests the effects of two versions of RiskProfile, a clinically-informed and a genetically-informed version of a patient-specific risk feedback tool, in comparison to usual care, on lung cancer screening and tobacco treatment. The trial assesses the multilevel effects of these precision risk feedback tools on the likelihood of clinicians to order lung cancer screening and tobacco treatment and of their patients to utilize these cancer prevention interventions.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: CLINICIANS: \- Primary care clinician with active caseload in participating clinics PATIENTS: * Patient of participating primary care clinician * Lung cancer screening naïve * Between 50 to 80 years of age, inclusive * Current or former smokers * Pack years ≥ 20 * English-speaking Exclusion Criteria: PATIENTS: * Lung cancer diagnosis * Current order placed for lung cancer screening

What they're measuring

Clinician ordering of lung cancer screening

Timeframe: From enrollment through 6 months post-intervention

Patient completion of lung cancer screening

Timeframe: From enrollment through 6 months post-intervention

Trial details

NCT IDNCT05627674

SponsorWashington University School of Medicine

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-08-31

View on ClinicalTrials.gov More Smoking trials